SaxoCell Conference 2026

SaxoCell Conference 2026
Go back

SaxoCell Conference 2026

From Lab to Life: Advancing Cell and Gene Therapies Together

Join us at the SaxoCell Conference 2026 in Dresden, where leading minds from science,industry, and politics come together to shape the future of safe and accessible cell and genetherapies — bridging innovation and implementation.

The SaxoCell Conference 2026 is your opportunity to engage with experts, innovators, and decision makers in the field of cell and gene therapies. As part of the BMBF Clusters4Future initiative, SaxoCell is one of Germany’s leading centres dedicated to researching new applications and production methods for personalised therapies and ‘living drugs’.

What to Expect:

  • Insights into the latest scientific advancements in cell and gene therapies.
  • Opportunities to network with professionals from academia, industry, and policy.
  • Discussions on how Germany is contributing to the future of Cell and Gene Therapy.

Date: 02 – 03 June 2026
Location: Penck Hotel, Dresden

Whether you’re a scientist, industry leader, or policymaker, the SaxoCell Conference offers a platform to
exchange ideas and collaborate on shaping the future of healthcare.

You can find more information about SaxoCell at www.saxocell.de

Register now to be part of this important event!

https://eveeno.com/saxocell_conference_2026

BioRN members receive a 20 % discount.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

The National Medical Products Administration (NMPA) in China has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic device in China. It is intended as a companion diagnostic to identify patients with MSI-high (MSI-H) solid tumors for treatment with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc., […]

read more
aimed analytics GmbH highlighted in deutsche-startups.de

aimed analytics GmbH highlighted in deutsche-startups.de

5 neue Startups: ONOX, aimed analytics, Recarbox, FORMIC, showroom.fm Es ist wieder soweit – neue Startups stehen in den Startlöchern! Hier sind einige spannende junge Unternehmen, die man kennen sollte. Heute werfen wir einen Blick auf diese Neugründungen: ONOX, aimed analytics, Recarbox, FORMIC und showroom.fm. deutsche-startups.de stellt heute erneut eine Auswahl junger Startups vor, die […]

read more
BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

Bridgetown, Barbados, January 27, 2026 – BioMed X, a leading innovation hub for pharma, today announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s PharmaNext Programme. The new global call for research proposals, entitled “AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados,” addresses one of the most pressing and underexplored […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp